Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Biocompatible Spherical Gold Nanoparticles Synthesis in Aqueous Tetraethylene Oxide Solution and Their Cellular Uptake.

Trouiller AJ, Béré E, Kalaani J, Evanno E, Fouchaq B, Roche J, Prestoz L, Napporn TW, Bertrand P.

J Nanosci Nanotechnol. 2019 Jul 1;19(7):3744-3754. doi: 10.1166/jnn.2019.16304.

PMID:
30764930
2.

Erratum: Roche, J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers, 2018, 10, 52.

Roche J.

Cancers (Basel). 2018 Mar 19;10(3). pii: E79. doi: 10.3390/cancers10030079.

3.

The Epithelial-to-Mesenchymal Transition in Cancer.

Roche J.

Cancers (Basel). 2018 Feb 16;10(2). pii: E52. doi: 10.3390/cancers10020052. Erratum in: Cancers (Basel). 2018 Mar 19;10(3):.

4.

Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer.

Evanno E, Godet J, Piccirilli N, Guilhot J, Milin S, Gombert JM, Fouchaq B, Roche J.

Clin Epigenetics. 2017 Aug 8;9:80. doi: 10.1186/s13148-017-0380-0. eCollection 2017.

5.

Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.

Roche J, Gemmill RM, Drabkin HA.

Cancers (Basel). 2017 Jun 24;9(7). pii: E72. doi: 10.3390/cancers9070072. Review.

6.

Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334-356.

Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H.

Cancers (Basel). 2016 Dec 15;8(12). pii: E114.

7.

Axon guidance molecule expression after cell therapy in a mouse model of Parkinson's disease.

Kalaani J, Roche J, Hamade E, Badran B, Jaber M, Gaillard A, Prestoz L.

Restor Neurol Neurosci. 2016 Nov 22;34(6):877-895.

PMID:
27858721
8.

Inside HDACs with more selective HDAC inhibitors.

Roche J, Bertrand P.

Eur J Med Chem. 2016 Oct 4;121:451-483. doi: 10.1016/j.ejmech.2016.05.047. Epub 2016 May 25. Review.

PMID:
27318122
9.

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.

PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016.

10.

Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells.

Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H.

Cancers (Basel). 2013 Apr 3;5(2):334-56. doi: 10.3390/cancers5020334. Erratum in: Cancers (Basel). 2016 Dec 15;8(12):.

11.

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA.

Cancer Res. 2013 Dec 1;73(23):7111-21. doi: 10.1158/0008-5472.CAN-13-1755. Epub 2013 Oct 11. Erratum in: Cancer Res. 2014 Jan 15;74(2):637.

12.

A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.

Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski I, Roche J, Papot S.

ChemMedChem. 2011 Jun 6;6(6):1006-10. doi: 10.1002/cmdc.201100114. Epub 2011 Mar 25. No abstract available.

PMID:
21442760
13.

ZEB1-responsive genes in non-small cell lung cancer.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA.

Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.

14.

Letter from the guest editors.

Roche J, Drabkin H.

Cell Adh Migr. 2010 Jan-Mar;4(1):94-5. No abstract available.

15.

Guidance molecules in lung cancer.

Nasarre P, Potiron V, Drabkin H, Roche J.

Cell Adh Migr. 2010 Jan-Mar;4(1):130-45. Epub 2010 Jan 7. Review.

16.

Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.

Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P.

J Med Chem. 2009 May 14;52(9):3112-5. doi: 10.1021/jm9002439.

PMID:
19385600
17.

ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J.

Neoplasia. 2009 Feb;11(2):157-66.

18.

Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.

Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S.

Bioorg Med Chem. 2008 Sep 1;16(17):8109-16. doi: 10.1016/j.bmc.2008.07.048. Epub 2008 Jul 23.

PMID:
18692397
19.

Semaphorins and their receptors in lung cancer.

Potiron VA, Roche J, Drabkin HA.

Cancer Lett. 2009 Jan 8;273(1):1-14. doi: 10.1016/j.canlet.2008.05.032. Epub 2008 Jul 14. Review.

20.

Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.

Charrier C, Roche J, Gesson JP, Bertrand P.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6142-6. Epub 2007 Sep 14.

PMID:
17897824

Supplemental Content

Loading ...
Support Center